Can Timing of Nontarget-vessel PCI Impact Patients with ACS & Multivessel Disease ?

In this cohort study of a large prospective registry of post-ACS, the researchers included a total of 1432 patients who underwent planned PCI (2009-2017). They evaluated the all‐cause death, recurrent myocardial infarction and urgent premature non–target‐vessel PCI.

Key findings of the study:

♦ After a year, the researchers found no significant differences in the crude or adjusted rates of the primary endpoint in early versus late PCI. (7.8% early versus 10.8% late, hazard ratio [HR], 0.72; adjusted HR, 0.80).

♦ Individual components were:

• All‐cause death: 1.5% versus 2.9%, HR, 0.52; adjusted HR, 0.62.
• Recurrent myocardial infarction: 4.2% versus 4.4%, HR, 0.97; adjusted HR, 1.03.
• Non–target‐vessel PCI, 3.9% versus 5.7%, HR, 0.97; adjusted HR, 1.19.

The authors concluded, "In patients with both ACS and MVD scheduled to undergo staged PCI after hospital discharge, early (<4 weeks) compared with late staged PCI (≥4 weeks) was associated with a similar rate of the primary endpoint all‐cause death, recurrent MI, urgent premature non–target‐vessel PCI in this single-centre and all‐comer population."

For further information:

DOI: https://doi.org/10.1161/JAHA.121.023129